Stocktoria
Fulcrum Therapeutics, Inc. FULC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-07-18
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $80.0M | $2.8M | $6.3M | $19.2M |
| Operating income | -$84.8M | -$21.9M | -$110.7M | -$112.6M | -$81.1M |
| Net income | -$74.9M | -$9.7M | -$97.3M | -$109.9M | -$80.8M |
| Operating cash flow | -$60.1M | -$2.2M | -$91.0M | -$97.0M | -$78.5M |
| Free cash flow | -$60.4M | -$2.5M | -$91.5M | -$99.0M | -$80.2M |
| Total assets | $366.3M | $260.7M | $257.7M | $226.7M | $235.0M |
| Total liabilities | $17.3M | $17.7M | $22.5M | $27.7M | $23.5M |
| Shareholders' equity | $349.0M | $243.0M | $235.2M | $198.9M | $211.5M |
| Ratios | |||||
| Operating margin | — | -27.4% | -3945.2% | -1774.9% | -423.0% |
| Net margin | — | -12.2% | -3470.1% | -1732.4% | -421.9% |
| FCF margin | — | -3.1% | -3261.1% | -1561.2% | -418.5% |
| Return on assets | -20.4% | -3.7% | -37.8% | -48.5% | -34.4% |
| Return on equity | -21.5% | -4.0% | -41.4% | -55.2% | -38.2% |
| Current ratio | 27.40 | 22.63 | 17.71 | 12.41 | 11.77 |
| Revenue growth | -100.0% | 2752.0% | -55.8% | -66.9% | 117.2% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 2,074,855 | $15.9M |
| RENAISSANCE TECHNOLOGIES LLC | 13,600 | $104,312 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001680581 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.